Written and maintained by CASRAI Editorial Board
Last updated
Short answer: USP chapter 1116, “Microbiological Control and Monitoring of Aseptic Processing Environments,” is the United States Pharmacopeia’s informational chapter on how to control and monitor microbial contamination where sterile products are made by aseptic processing. It is guidance on a monitoring program, not a table of legal limits. Numeric action levels most people quote come from FDA’s 2004 aseptic processing guidance, and the two documents measure results in different ways.
Definition and scope
The USP-NF page for chapter 1116 describes it as covering environments in which the risk of microbial contamination is controlled by aseptic processing: sterile drug products, bulk sterile drug substances, sterile intermediates, excipients and some medical devices. It states that aseptic processing environments are “far more critical in terms of patient risk” than other manufacturing environments (USP-NF, checked 2026-10-29).
The chapter also defines an advanced aseptic process as one in which direct intervention with open product containers is not required and never permitted. That definition separates closed or automated systems from conventional cleanroom filling that relies on trained operators.
The chapter number sits in the 1000-and-above range of USP-NF, which holds general information chapters. It supports a monitoring program; it is not a compendial test with a pass/fail result.
How the monitoring program is meant to work
The clearest plain-language description of how to run and read an environmental monitoring program comes from FDA’s Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice (September 2004, checked 2026-10-29). Its text can be turned into a short checklist:
- Write the program down. Procedures should cover sampling frequency, timing, duration, sample size, equipment, alert and action levels, and the response to deviations.
- Set levels from your own data. Levels should consider historical databases, media fills, cleanroom qualification and sanitization studies.
- Do not average away a problem. FDA notes that “averaging of results can mask unacceptable localized conditions.”
- Treat alert and action levels differently. A result at the alert level “urges attention to the approaching action conditions”; a result at the action level “should prompt a more thorough investigation.”
- Trend by place and person. Trend reports should be organized by location, shift, room and operator.
- Watch incidence, not only single values. An increased incidence of contamination over a period is “an equal or more significant trend to be tracked.” A single result above the action level, absent an adverse trend, should still trigger an evaluation.
Contamination recovery rate versus colony counts
A frequent source of confusion is that the chapter has moved over successive revisions from judging each sample by a colony-forming unit (cfu) count toward describing the contamination recovery rate. In an earlier edition, USP 38-NF 33, the rate is defined as the rate at which environmental samples are found to contain any level of contamination. A trade article on the proposed revision (Pharmaceutical Online, 19 August 2016) describes it as expressing values as a maximum allowed percentage of contaminated samples rather than as conventional cfu enumeration.
The two ideas answer different questions. A cfu limit asks how much growth one sample showed. A recovery rate asks how often samples showed any growth over a period. The comparison below keeps each figure tied to the edition or document it comes from.
FDA 2004 Table 1: recommended levels by ISO class
| ISO class | Particles ≥0.5 µm per m³ | Active air, cfu per m³ | Settle plate (90 mm, 4 h), cfu |
|---|---|---|---|
| ISO 5 | 3,520 | 1 | 1 |
| ISO 6 | 35,200 | 7 | 3 |
| ISO 7 | 352,000 | 10 | 5 |
| ISO 8 | 3,520,000 | 100 | 50 |
Source: FDA, September 2004, Table 1. FDA states that you may find it appropriate to establish alternate microbiological action levels, and that samples from ISO 5 environments “should normally yield no microbiological contaminants.” Settling plates are described as optional.
USP 38-NF 33: suggested initial contamination recovery rates
| Environment | Suggested initial rate (samples with any growth) |
|---|---|
| Isolator or closed RABS | below 0.1% |
| ISO 5 | below 1% |
| ISO 6 | below 3% |
| ISO 7 | below 5% |
| ISO 8 | below 10% |
These figures come from an earlier edition (USP 38-NF 33), which states that its numerical monitoring values are not intended to represent limits or specifications but are strictly informational. The current USP-NF text governs, and it may differ.
Where it matters for labs, clinics and supply decisions
Chapter 1116 matters wherever sterile product is filled or handled aseptically, and the same monitoring vocabulary appears in several areas of the site:
- The sampling tools behind the numbers, such as air samplers, settle plates and particle counters, are compared in viable air sampler options and covered operationally in the pharmaceutical environmental monitoring guide.
- The particle-count column in FDA’s table is defined by cleanroom class; see ISO Class 5 requirements.
- Process simulation is a separate check on the same aseptic process; see media fill aseptic process simulation.
- For the European expectations on sterile manufacturing, see EU GMP Annex 1.
- Pharmacy compounding has its own chapter; see USP 797 sterile compounding.
Common misunderstandings
“Chapter 1116 sets the limits.”
It is an informational chapter. The cfu action levels in the table above are FDA’s recommended levels from 2004, and FDA itself says alternate levels may be appropriate.
“A recovery rate replaces trending.”
No. Both FDA’s text and the recovery-rate idea point toward watching incidence over time. A rate is one way to express that trend.
“One clean average means the room is fine.”
FDA warns that averaging can hide a localized problem, which is why results are trended by location, shift, room and operator.
“It is the same as USP 797.”
No. Chapter 797 addresses sterile compounding; chapter 1116 addresses microbiological control and monitoring of aseptic processing environments.
FAQ
What is USP 1116?
It is the USP-NF general information chapter titled “Microbiological Control and Monitoring of Aseptic Processing Environments,” covering environments where contamination risk is controlled by aseptic processing.
Does USP 1116 give cfu limits?
FDA’s 2004 guidance gives recommended cfu levels by ISO class. The USP chapter is informational and, in the earlier USP 38-NF 33 edition, introduced contamination recovery rates as a complementary measure. Use the current USP-NF for the chapter’s present wording.
What is a contamination recovery rate?
The rate at which environmental samples are found to contain any level of contamination, expressed as a percentage of samples.
What is the difference between an alert level and an action level?
Per FDA, an alert-level result calls for attention to approaching action conditions; an action-level result should prompt a more thorough investigation.
Sources
- USP-NF, “Microbiological Control and Monitoring of Aseptic Processing Environments” (chapter 1116), introduction page: https://doi.usp.org/USPNF/USPNF_M99835_01_01.html, checked 2026-10-29.
- FDA, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing – CGMP, September 2004: https://www.fda.gov/media/71026/download, checked 2026-10-29.
- USP 38-NF 33, chapter 1116 (earlier edition, third-party mirror): https://www.drugfuture.com/Pharmacopoeia/usp38/data/v38332/usp38nf33s2_c1116.html, checked 2026-10-29.
- Pharmaceutical Online, “USP Microbiological Control Of Aseptic Processing Environments And Its Implications,” 19 August 2016: https://www.pharmaceuticalonline.com/doc/usp-microbiological-control-of-aseptic-processing-environments-and-its-implications-0001, checked 2026-10-29.
